MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

PFE · NYSE

Pfizer, Inc.

Health Care · Biotechnology: Pharmaceutical Preparations

Reference price$25.25As of Jul 28, 2026
Market capitalization$144B
52-week range$23.11–$28.75
S&P 500 portfolio weight0.22%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$25.00-1.0% vs. reference
Average$28.50+12.9% vs. reference
High$35.00+38.6% vs. reference
6 Buy14 Hold2 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 4, 2026Jun 2026
Consensus EPS$0.685 estimates
Expected range$0.66–$0.69Low to high EPS
Dec 2026$2.96Street EPS consensus
Dec 2027$2.85Street EPS consensus
Dec 2028$2.33Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue-1.6% YoY$62.58B$63.63B
Operating income$14.24B$12.41B
Net income$7.81B$8.06B
Operating cash flow$11.7B$12.74B
Capital expenditures($2.63B)($2.91B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings

Zacks

Pfizer (PFE) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Zacks

Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect?

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.